Xenon Pharmaceuticals Inc.

The current price of XENE is $37.68 — it has decreased by 3.85% since the previous close. Data as of Nov 5, 2026.

XENE is up 0.37% over the past week, up 0.29% over the past month and down 2.53% over the past year. The price is below its 200-day moving average of $52.33.

Analysts' average 12-month price target for XENE is $68.63, which implies 82.14% upside from the current price. Individual estimates range from $46.00 to $90.00.

Of the 18 analysts covering Xenon Pharmaceuticals Inc., 3 rate it a strong buy, 14 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Xenon Pharmaceuticals Inc. has a market capitalization of $3.65B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Xenon Pharmaceuticals Inc. posted a loss of $1.11 per share against an estimate of -$1.14, beating expectations by 2.63%. Upcoming reports are listed in the earnings calendar.

Xenon Pharmaceuticals Inc. has not paid any dividends over the past year.

Companies most comparable to Xenon Pharmaceuticals Inc. include Neurocrine Biosciences, Inc., Jazz Pharmaceuticals plc, Praxis Precision Medicines, Inc., Axsome Therapeutics, Inc. and Acadia Pharmaceuticals Inc.

In the latest trading session XENE moved between $37.57 and $39.34, a range of 4.70% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Xenon Pharmaceuticals Inc. shows a sell rating today. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Xenon Pharmaceuticals Inc. is sell. Technical ratings are indicators, not investment advice.

Over the past 52 weeks XENE has traded between $33.38 and $72.66. The current price is 48.14% below its 52-week high.